Evaluation of Intra pleural Chemotherapy with Cisplatin in Iranian Cancer Patients with Malignant Pleural Effusion

SM Lung Cancer: Research & Therapy, 2017; 1(1): 1002.

Distributed under Creative Commons CC-BY 4.0

Arda Kiani¹, Kimia Taghavi², Maryam Esmaeilzadeh², Adnan Khosravi³, Sharareh Seifi⁴, Atefeh Abedini^2*

1-Tracheal Diseases Research Center, Shahid Beheshti University of Medical Sciences, Iran

2- Chronic Respiratory Diseases Research Center, Shahid Beheshti University of Medical Sciences, Iran

3- Tobacco Prevention and Control Research Center, Shahid Beheshti University of Medical Sciences, Iran

4- Medical Hematology/ Oncology, National Institute of Tuberculosis and Lung Disease (NITLD), Iran

*Corresponding author: Atefeh Abedini, Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran, Email: dr.abedini110@sbmu.ac.ir

Abstract

Background:Malignant pleural effusion is a common problem in patients with advanced malignancies and compromised the short-lived survival of these patients. These effusions can be resistant to the treatment such as systemic chemotherapy, pleurodesis with sclerosantagents and recurrent drainage. Therefore, new therapeutic options are needed. The purpose of this study was to evaluate the effectiveness of intrapleural chemotherapy with Cisplatin for the management of MPE in lung, breast and mesothelioma cancers.

Materials and methods:Twenty-one cancer patients with MPE were enrolled in this study. Cisplatin was injected through a catheter at a dose of 30mg /m2, and this procedure was performed 3 times at intervals of two weeks. Patients were evaluated for side effects and responses to the treatment every two weeks and one month after the last treatment.

Results:Among the assessable 18 patients, complete response and partial response were 9 (50%) and 4 (22.2%) patients, respectively (overall response rate 72.2%). Dyspnea was improved in 13 (72.2%) patients and had no change in 5 (27.8%) patients. One patient did not refer after the first intrapleural injection. Also two patients died during the study. None of the patients had side effects of grade 3 and 4.

Conclusion:The results of this trial study showed that using of Intrapleural Chemotherapy with cisplatin in the management of patients with MPE in lung, breast and mesothelioma cancers is effective and safe.

Keywords: Malignant pleural effusion; Intrapleural chemotherapy; Cisplatin

References

1. Monfared ZE, Khosravi A, Naini AS, Radmand G, Khodadad K. Analysis of Cisplatin-Induced Ototoxicity Risk Factors in Iranian Patients with Solid Tumors: A Cohort, Prospective and Single Institute Study. Asian Pacific Journal of Cancer Prevention. 2017; 18: 753-758.

2. Mirhosseini SM, Fakhri M, Mozaffary A, Lotfaliany M, Behzadnia N, Ansari Aval Z, et al. Risk factors affecting the survival rate in patients with Symptomatic Pericardial Effusion undergoing surgical intervention. Interact Cardiovasc Thorac Surg. 2012; 16: 495-500.

3. Fahimi F, Khodadad K, Amini S, Naghibi F, Salamzadeh J, Baniasadi S. Evaluating the effect of Zingiber Officinalis on Nausea and Vomiting in patients receiving Cisplatin based regimens. Iranian journal of Pharmaceutical Research: IJPR. 2011; 10: 379.

4. Khosravi A, Esfahani-Monfared Z, Karimi SH, Emami H, Khodadad K. Comparing Docetaxel with Gemcitabine as second-line chemotherapy in patients with advanced non-small cell lung cancer: A single institute randomized phase II study. J Cancer Res Ther. 2015; 3: 1-7.

5. Karimi S, Yousefi F, Seifi S, Khosravi A, Nadji SA. No evidence for a role of Merkel cell Polyomavirus in small cell lung cancer among Iranian subjects. Pathology-Research and Practice. 2014; 210: 836-839.

6. Tafsiri E, Darbouy M, Shadmehr MB, Zagryazhskaya A, Alizadeh J, Karimipoor M. Expression of miRNAs in non-small-cell lung carcinomas and their association with clinicopathological features. Tumor Biology. 2015; 36:1603-12.

7. Jacobs RE, Gu P, Chachoua A. Reactivation of Pulmonary Tuberculosis during Cancer Treatment. International Journal of Mycobacteriology. 2015; 4: 337-340.

8. ShaloamDasari, Paul Bernard Tchounwou. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 2014; 740: 364-378.

9. Miller RP1, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin nephrotoxicity. Toxins. 2010; 2: 2490-2518.

10. Nan DU, Xiaosong Li, Fang Li, Hui Zhao, Zhongyi Fan, Junxun Ma, et al. Intrapleural combination therapy with bevacizumab and cisplatin for nonsmall cell lung cancer mediated malignant pleural effusion. Oncology Reports. 2013; 29: 2332-2340.

11. Light RW, Amber D. Malignant Pleural Effusions. In: Pleural Diseases. Williams and Wilkins. 1995; 94: 116.

12. Fredric W, Grannis J, JY Kim, Lily Lai. Fluid complications: Malignant pleural effusion. Oncology Journal. 2015; 73: 213-216.

13. Figlin R, Mendoza E, Piantadosi S, Rusch V. Intrapleural Chemotherapy without Pleurodesis for Malignant Pleural Effusions: LCSG Trial 861. Chest. 1994; 106: 363S-366S.

14. Baba T, Uramoto H, Kuwata T, Takenaka M, Chikaishi Y, Oka S, et al. Intrapleural chemotherapy improves the survival of non-small cell lung cancer patients with positive pleural lavage cytology. Surg Today. 2013; 43: 648-653.

15. Kim KW, Park SY, Kim MS, Kim SC, Lee EH, Shin SY, et al. Intrapleural chemotherapy with cisplatin and cytarabine in the management of malignant pleural effusion. Cancer Res Treat. 2004; 36: 68-71.